Nidan Laboratories & Healthcare Ltd
Nidan Laboratories & Healthcare Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue, margins and capex.
Top 10 Healthcare Services companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Nidan Laboratories & Healthcare Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the half year ended 30th September 2026 was Rs 1,201.76 lakhs, compared to Rs 1,312.10 lakhs for the same period in 2025, reflecting a year-on-year decrease. EBITDA for the half year ended 30th September 2026: Rs 187.28 lakhs (Operating Profit Before Working Capital Changes from cash flow statement).
From Nidan Laboratories & Healthcare Ltd's Q2 FY27 earnings-call transcript · updated 7 Nov 2026.
How did Nidan Laboratories & Healthcare's revenue grow in the September 2026 quarter?
- Revenue from operations for the half year ended 30th September 2026 was Rs 1,201.76 lakhs, compared to Rs 1,312.10 lakhs for the same period in 2025, reflecting a year-on-year decrease.
- Total income, including other income, was Rs 1,348.37 lakhs for H1 2026 versus Rs 1,429.06 lakhs in H1 2025, also showing a decline year-on-year.
What happened to Nidan Laboratories & Healthcare's margins in Q2 FY27?
See what Nidan Laboratories & Healthcare Ltd said on profitability & margins — free account, 30 seconds.
What capex is Nidan Laboratories & Healthcare planning?
See what Nidan Laboratories & Healthcare Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Nidan Laboratories & Healthcare raising money or cutting debt?
See what Nidan Laboratories & Healthcare Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Nidan Laboratories & Healthcare's order book?
See what Nidan Laboratories & Healthcare Ltd said on order book & pipeline — free account, 30 seconds.
Continue your research
Others in Healthcare Services this season
- Suven Life Sciences (Q2 FY27)
91.92 lakhs for the quarter ended September 30, 2025, indicating a revenue increase of approximately 30.3%. Key results statement takeaways from Suven Life Scie
- Aster DM Quality (Q2 FY27)
Q2 FY27 revenue: INR 2,829 Cr, up 19% YoY from INR 2,382 Cr in Q2 FY26 (Page 6, 9, 10). Key investor presentation takeaways from Aster DM Quality Care Ltd's Q2
- Fortis Healthcare (Q2 FY27)
Q2FY27 consolidated revenue: INR 2,735 Cr, up 17.3% YoY (Q2FY26: INR 2,331 Cr) [Pages 11, 33] . Key investor presentation takeaways from Fortis Healthcare Ltd's
- Dr Agarwal's Hea (Q2 FY27)
Q2 FY27 revenue from operations: ₹655 Cr, up 31.4% YoY from ₹499 Cr in Q2 FY26 (Page 24) . Key investor presentation takeaways from Dr Agarwals Health Care Ltd'
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM QualityGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Nidan Laboratories & Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Nidan Laboratories & Healthcare Ltd Q2 FY27 results?
Revenue from operations for the half year ended 30th September 2026 was Rs 1,201.76 lakhs, compared to Rs 1,312.10 lakhs for the same period in 2025, reflecting a year-on-year decrease. EBITDA for the half year ended 30th September 2026: Rs 187.28 lakhs (Operating Profit Before Working Capital Changes from cash flow statement).
What is Nidan Laboratories & Healthcare Ltd share price analysis?
Nidan Laboratories & Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 9.8 with a market cap of ₹17 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Nidan Laboratories & Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.